These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 21058895

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E, Caracas-Portilla NA, Cardoso-Saldaña G, Medina-Urrutia A, Jorge-Galarza E, Juárez-Rojas JG.
    Am J Cardiol; 2012 Mar 01; 109(5):636-41. PubMed ID: 22169129
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ, Merikle E, Jones J.
    Clin Ther; 2007 Apr 01; 29(4):742-50. PubMed ID: 17617298
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
    Chapman MJ.
    Curr Med Res Opin; 2005 Apr 01; 21 Suppl 6():S17-22. PubMed ID: 16138937
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 01; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 11. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 01; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 12. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 25; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 16. Serum lipid profiles including non-high density lipoprotein cholesterol levels in Turkish school-children.
    Uçar B, Kiliç Z, Dinleyici EC, Colak O, Güneş E.
    Anadolu Kardiyol Derg; 2007 Dec 25; 7(4):415-20. PubMed ID: 18065339
    [Abstract] [Full Text] [Related]

  • 17. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr 25; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 18. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB.
    Am J Cardiol; 2009 Dec 15; 104(12):1689-94. PubMed ID: 19962476
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.